Non-invasive fetal RHD genotyping to guide targeted anti-D prophylaxis–an external quality assessment workshop | Clausen FB, et al | Vox sanguinis | May 2019

Clausen FB, Barrett AN, Noninvasive Fetal RHD Genotyping EQA2017 Working Group, Akkök CA, Armstrong‐Fisher S, Bergström KD, Boggione CT, Bævre MS, Choolani M, Christiansen M, Cotorruelo C. Noninvasive fetal RHD genotyping to guide targeted anti‐D prophylaxis–an external quality assessment workshop. Vox sanguinis. 2019;114(4):386-93.

 

Nonacus Products: Prenatal healthcare

Background and Objectives

Fetal RHD genotyping of cell-free fetal DNA from RhD-negative pregnant women can be used to guide targeted antenatal and postnatal anti-D prophylaxis for the prevention of RhD immunization. To assure the quality of clinical testing, we conducted an external quality assessment workshop with the participation of 28 laboratories.

Materials and Methods

Aliquots of pooled maternal plasma were sent to each laboratory. One sample was positive, and the second sample was negative for fetal RHD, verified by pre-workshop testing using quantitative real-time PCR (qPCR) analysis of RHD exons 4, 5, 7 and 10. Plasma samples were shipped at room temperature. A reporting scheme was supplied for data collection, including questions regarding the methodological setup, results and clinical recommendations. Different methodological approaches were used, all employing qPCR with a total of eight different combinations of RHD exon targets. The samples were tested blindly.

Noninvasive fetal RHD genotyping to guide targeted anti-D prophylaxis–an external quality assessment workshop

Fetal RhD